A Multidisciplinary Model Predicts Clinical Response in Relapsed Multiple Myeloma

被引：0
|
作者：
Shain, Kenneth H. [1 ]
Silva, Ariosto [2 ]
Meads, Mark B. [3 ]
Distler, Allison [3 ]
Jacobson, Timothy [2 ]
Gatenby, Robert [2 ]
Baz, Rachid [1 ]
Silva, Maria [4 ]
Rebatchouk, Dmitri [5 ]
Cubitt, Chris [4 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Intergrated Math Oncol, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] nPharmakon, Piscataway, NJ USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Clinical synergism of Bortezomib and chemotherapy in relapsed and refractory multiple myeloma.
    Mazumder, A
    Chauvin, E
    Curran, K
    Disperati, P
    Jagannath, S
    BLOOD, 2003, 102 (11) : 390B - 390B
  • [32] Clinical Significance of Spatial Heterogeneity in Newly Diagnosed and Relapsed Multiple Myeloma
    Merz, Maximilian
    Wei, Lei
    Hu, Qiang
    Merz, Almuth Maria Anni
    Wang, Jie
    Belal, Ahmed
    Alberico, Ronald
    Rondeau, Cherie
    Celotto, Kimberly
    Block, AnneMarie W.
    Mohammadpour, Hemn
    Wallace, Paul K.
    Tario, Joseph Dennis
    Luce, Jesse
    Glenn, Sean
    Singh, Prashant K.
    Barnidge, David
    Liu, Song
    McCarthy, Philip L.
    Hillengass, Jens
    BLOOD, 2021, 138
  • [33] Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives
    Jakubowiak, Andrzej
    SEMINARS IN HEMATOLOGY, 2012, 49 (03) : S16 - S32
  • [34] Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab
    Chari, Ajai
    Krishnan, Amrita
    Rasche, Leo
    Ye, Jing Christine
    Garfall, Alfred
    Popat, Rakesh
    Lipe, Brea
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara
    Tomlinson, Chalmer
    Hilder, Brandi
    Tolbert, Jaszianne
    Renaud, Thomas
    Smit, M. Damiette
    Gray, Kathleen
    Kane, Colleen
    Heuck, Christoph
    van de Donk, Niels W. C. J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10): : 665 - +
  • [35] Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Jung, Sung-Hoon
    Lee, Seung-Shin
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [36] A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
    Franken, B.
    van de Donk, N. W. C. J.
    Cloos, J. C.
    Zweegman, S.
    Lokhorst, H. M.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (06) : 330 - 344
  • [37] Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma
    Mark, Tomer M.
    Coleman, Morton
    Niesvizky, Ruben
    LEUKEMIA RESEARCH, 2014, 38 (05) : 517 - 524
  • [38] Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Kumar, S
    Gertz, MA
    Dispenzieri, A
    Lacy, MQ
    Geyer, SM
    Iturria, NL
    Fonseca, R
    Hayman, SR
    Lust, JA
    Kyle, RA
    Greipp, PR
    Witzig, TE
    Rajkumar, SV
    MAYO CLINIC PROCEEDINGS, 2003, 78 (01) : 34 - 39
  • [39] Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
    Martin, Thomas
    Mikhael, Joseph
    Hajek, Roman
    Kim, Kihyun
    Suzuki, Kenshi
    Hulin, Cyrille
    Garg, Mamta
    Quach, Hang
    Sia, Hanlon
    George, Anup
    Konstantinova, Tatiana
    Risse, Marie-Laure
    Asset, Gaelle
    Mace, Sandrine
    van de Velde, Helgi
    Moreau, Philippe
    BLOOD ADVANCES, 2022, 6 (15) : 4506 - 4515
  • [40] Therapy of relapsed and relapsed-refractory Multiple Myeloma
    Driessen, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 8 - 8
12345